Research Brief
Sermorelin: Research Applications
👶 Pediatric GHD (Formerly FDA-registered)
The Geref International Study Group multicenter trial (n=110) estabeleceu Sermorelin for pediatric GH deficiency. Growth velocity aumentou from 4.1 cm/yr to 8.0 cm/yr at 6 months, with 74% good response rate. No excessive IGF-1 generation or glucose changes. [2]
🔬 Diagnostic Evaluation
A single IV dose (1 µg/kg) is used to assess pituitary GH reserve, distinguishing hypothalamic vs pituitary causes of GHD. Fewer false positives comparado(a) a outro(a) provocative tests. [2]
🧓 Anti-Aging / Age-Related GH Decline
In healthy elderly subjects (n=19), 16-week aplicacao em pesquisa produziu +107% nocturnal GH (men), +1.26 kg lean mass, melhorou sensibilidade a insulina, and aprimorou well-being. High-dose (1 mg BID) restaurou IGF-1 to young adult levels in men aged 60–78. [7] [12]
🧠 Cognitivo Function & Sleep
Sermorelin facilita slow-wave sleep, que is correlated with nocturnal GH secretion. Modulates age-related decline no(a) somatotropic axis. [13]
🛡️ Immunosenescencia
In aging adults, Sermorelin aprimorou significativamente funcao imunologica: B cell +30%, T cell responsiveness +50–70%, IL-2 receptor expression +70%, transient IgG/IgM/IgA aumenta. [11]
💪 Body Composition / Hypogonadal Men
A retrospective study (n=14) of hypogonadal men on testosterone + Sermorelin/GHRP-2/GHRP-6 showed significant IGF-1 aumenta at 90, 180, and 270 days. Lean body mass and visceral fat improvements. [14]
🎯 Oncology — Glioma
Bioinformatics screening of 4,865 drugs identificado(a) Sermorelin como o(a) most eficaz candidate for recurrent glioma (P<0.0001). In vitro, it inibiu U87/LN229 cell growth dose-dependentely by blocking cell cycle and negatively regulating immune checkpoints. [10]
Referencias
- Chang Y, Huang R, Zhai Y, et al. A potentially eficaz compound for sujeitos de estudo with recurrent glioma: sermorelin. Ann Transl Med, 9(5), 406, 2021.
- Prakash A, Goa KL. Sermorelin: a review of its use no(a) diagnosis and investigation of children with idiopathic hormonio do crescimento deficiency. BioDrugs, 12(2), 139-157, 1999.
- Walker RF. Sermorelin: a better approach to management of adult-onset hormonio do crescimento insufficiency? Clin Interv Aging, 1(4), 307-308, 2006.
- Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of tolerability or Effectiveness. Fed Register, 78(42), 14095-14096, 2013.
- Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of hormonio do crescimento secretagogues no(a) modern management of composicao corporal in hypogonadal males. Transl Androl Urol, 9(Suppl 2), S149-S159, 2020.
- Grossman AB, Savage MO, Lytras N, Besser GM. Responses to analogues of hormonio do crescimento releasing hormone in normals e em GH-deficient children and young adults. Clin Endocrinol (Oxf), 21(3), 321-330, 1984.
- Corpas E, Harman SM, Piñeyro MA, et al. Growth hormone (GH)-releasing hormone-(1-29) duas vezes ao dia reverses a diminuicaod GH and insulinlike fator de crescimento-I levels in old men. J Clin Endocrinol Metab, 75(2), 530-535, 1992.
- Heiman ML, Nekola MV, Murphy WA, Lance VA, Coy DH. An extremely sensitive in vitro model for elucidating structure-activity relationships of hormonio do crescimento-releasing factor analogs. Endocrinology, 116(1), 410-415, 1985.
- Gelander L, Lindstedt G, Selstam G, et al. Effects of agudo(a) IV injection of two hormonio do crescimento-releasing hormones on serum GH e outros(as) pituitary hormones in short children. Horm Res, 31(5-6), 213-220, 1989.
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of longo prazo administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab, 82(5), 1472-1479, 1997.
- Khorram O, Yeung M, Vu L, Yen SS. Effects of [norleucine27]hormonio do crescimento-releasing hormone (GHRH) (1-29)-NH2 administration no(a) sistema imunologico of aging men and women. J Clin Endocrinol Metab, 82(11), 3590-3596, 1997.
- Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of GHRH 1-29 in healthy elderly men. Metabolism, 46(1), 89-96, 1997.
- Vitiello MV, Schwartz RS, Moe KE, Mazzoni G, Merriam GR. Treating age-related changes in somatotrophic hormones, sleep, and cognition. Dialogues Clin Neurosci, 3(3), 229-236, 2001.
- Sigalos JT, Pastuszak AW, Allison A, et al. Growth Hormone Secretagogue aplicacao em pesquisa in Hypogonadal Men Raises Serum IGF-1 Levels. Am J Mens Health, 11(6), 1752-1757, 2017.
- Schally AV, Wang H, He J, et al. Agonists of hormonio do crescimento-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH. PNAS, 115(47), 12028-12033, 2018.
- Jaszberenyi M, Rick FG, Popovics P, et al. Potentiation of cytotoxic chemotherapy by hormonio do crescimento-releasing hormone agonists. PNAS, 111(2), 781-786, 2014.
- Soule SG, King JA, Millar RP. Incorporation of D-Ala2 in GHRH-(1-29)-NH2 aumenta meia-vida and diminui metabolic depuracao in normal men. J Clin Endocrinol Metab, 79(4), 1208-1211, 1994.
- Merriam GR, Buchner DM, Prinz PN, Schwartz RS, Vitiello MV. Potential applications of GH secretagogs no(a) evaluation and investigation do(a) age-related decline in GH secretion. Endocrine, 7(1), 49-52, 1997.
- Walker RF, Yang SW, Bercu BB. Robust Growth Hormone (GH) secretion in aged female rats co-administered GH-releasing hexapeptide (GHRP-6) and GH-releasing hormone (GHRH). Life Sci, 49(20), 1499-1504, 1991.
- Rafferty B, Coy DH, Poole S. Pharmacokinetic evaluation of superactive analogues of hormonio do crescimento-releasing factor (1-29)-amide. Peptides, 9(1), 207-209, 1988.
Perguntas de Pesquisa Relacionadas
APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.